![]() |
市場調查報告書
商品編碼
1747141
日本心血管設備市場規模、佔有率、趨勢及預測(按設備類型、應用、最終用戶和地區),2025 年至 2033 年Japan Cardiovascular Devices Market Size, Share, Trends and Forecast by Device Type, Application, End User, and Region, 2025-2033 |
2024年,日本心血管設備市場規模達330萬美元。展望未來, IMARC Group預計到2033年,該市場規模將達到701萬美元,2025-2033年期間的複合年成長率(CAGR)為8.08%。人口老化、心血管疾病發生率上升以及技術進步是推動市場發展的因素。關鍵細分市場包括心律調節器、支架和監測設備。政府措施和不斷增加的醫療保健投資支撐著市場成長,而監管政策則影響產品的核准和應用。
微創心血管手術需求不斷成長
由於人口老化和導管治療技術的進步,日本對微創 (MI) 心血管設備的需求日益成長。經導管主動脈瓣置換術 (TAVR) 和經皮冠狀動脈介入治療 (PCI) 的採用率正在上升,這減少了住院時間並加快了患者康復。日本醫療器材公司正在投資機器人輔助手術和下一代導管,以提高精準度。在日本藥品和醫療器材綜合機構 (PMDA) 的指導下,監管環境正在簡化突破性技術的核准,從而加快市場准入。此外,人工智慧 (AI) 正在提高心血管影像診斷的精準度,協助早期介入方案的發展。例如,2024 年 9 月,總部位於日本的 Cardio Intelligence 公司推出了 SmartRobin AI,這是一款由可解釋的人工智慧驅動的心電圖監測系統,可快速檢測心房顫動,從而提高中風風險評估和心血管護理診斷的準確性。此外,隨著政府對家庭醫療保健的支持,穿戴式心電圖儀和植入式循環記錄器等遠端監測設備也越來越受歡迎。這一趨勢符合日本「價值導向醫療」的理念,強調成本效益和病患治療效果。隨著報銷政策的轉變,市場可望預期微創心血管解決方案將迎來成長。
人工智慧整合心血管診斷的成長
人工智慧正在改變日本的心血管診斷,改善早期疾病檢測和預測分析。人工智慧驅動的超音波心動圖和電腦斷層掃描 (CT) 成像儀能夠更快、更準確地診斷心臟病。大型研究中心和醫院正在應用人工智慧即時監測心臟,減輕醫護人員的負擔。機器學習技術正被整合到電子健康記錄 (EHR) 中,用於預測心臟衰竭風險,從而實現預防性治療。日本對數位健康創新的關注正促使醫療科技公司與人工智慧新創公司展開合作,以加速智慧診斷設備的部署。政府對個人化醫療的推動也推動了人工智慧賦能的心血管護理,以便根據基因和生活方式因素制定精準的治療方案。隨著人工智慧減少診斷錯誤並提高工作流程效率,其在心血管設備中的應用正在不斷增加,從而改善了患者管理並節省了長期醫療成本。例如,2024 年 9 月,奧林巴斯在歐洲、亞洲和大洋洲推出了 VISERA S,這是一款具有 NBI 和頻閃功能的一體化成像平台,透過改進的可視化和簡化的工作流程增強了耳鼻喉診斷。
穿戴式和遠端心臟監測設備的擴展
隨著日本人口老化和心臟病發病率的上升,穿戴式和遠端心臟監測設備正在迅速普及。內建心電圖的智慧手錶、手持式動態心電圖監測儀和植入式心臟事件記錄器正成為預防心臟病學的基石。 5G 連接的出現正在加速即時資料傳輸,使醫生能夠遠端監測患者並在危急事件發生前發現異常。日本設備製造商正在研發小巧易用、電池續航力更長的穿戴設備,以提高患者依從性。隨著日本加快醫療數位化進程,日本藥品生產和醫療器材管理局 (PMDA) 的支持正在推動尖端遠距醫療解決方案的快速核准。保險公司開始為遠端監測服務提供報銷,進一步推動了市場擴張。隨著診所和醫院部署基於雲端的心臟監測系統,在日本不斷變化的心血管護理環境中,數據驅動的資訊正在最大限度地最佳化治療方案,降低再入院率,並改善患者預後。
市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外,報告還提供了所有主要公司的詳細資料。
The Japan cardiovascular devices market size reached USD 3.30 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 7.01 Million by 2033, exhibiting a growth rate (CAGR) of 8.08% during 2025-2033. The market is driven by an aging population, rising cardiovascular diseases, and technological advancements. Key segments include pacemakers, stents, and monitoring devices. Government initiatives and increasing healthcare investments support market growth, while regulatory policies influence product approvals and adoption.
Rising Demand for Minimally Invasive Cardiovascular Procedures
Japan is facing a higher demand for minimally invasive (MI) cardiovascular devices owing to an aging population and improved catheter-based treatments. The adoption of transcatheter aortic valve replacement (TAVR) and percutaneous coronary interventions (PCI) is rising, reducing hospital stays and accelerating recovery. Japanese medical device companies are investing in robotics-assisted procedures and next-generation catheters to improve precision. The regulatory environment, under the guidance of the Pharmaceuticals and Medical Devices Agency (PMDA), is making approval easier for groundbreaking technologies, permitting quicker market entry. Furthermore, artificial intelligence (AI) is improving the precision of cardiovascular imaging diagnostics, aiding early intervention protocols. For example, in September 2024, Japan-based Cardio Intelligence introduced SmartRobin AI, an ECG monitoring system powered by explainable AI for fast atrial fibrillation detection, enhancing stroke risk assessment and diagnostic accuracy in cardiovascular care. Additionally, with home healthcare being supported by the government, remote monitoring devices such as wearable ECGs and implantable loop recorders are also becoming popular. The trend is in support of Japan's value-based medicine drive, stressing cost-effectiveness and patient outcome. With shifting reimbursement policies, the market can anticipate increased growth in minimally invasive cardiovascular solutions.
Growth of AI-Integrated Cardiovascular Diagnostics
AI is transforming cardiovascular diagnostics in Japan, improving early disease detection and predictive analytics. AI-driven echocardiography and computed tomography (CT) imaging machines are enabling faster, more accurate diagnosis of heart disease. Large research centers and hospitals are applying AI in real-time monitoring of the heart, reducing the burden on healthcare personnel. ML technologies are being integrated into electronic health records (EHRs) for predicting risks of heart failure, allowing preventive treatment modalities. The focus on digital health innovation in Japan is inducing collaborations between medtech firms and AI startups to accelerate the deployment of intelligent diagnostic equipment. The government drive in personalized medicine is also driving AI-enabled cardiovascular care so that precise treatment plans are delivered based on gene and lifestyle factors. As AI reduces diagnostic errors and increases workflow efficiency, its use in cardiovascular devices is increasing, leading to improved patient management and long-term healthcare cost savings. For instance, in September 2024, Olympus launched VISERA S, an all-in-one imaging platform with NBI and stroboscopy, across Europe, Asia, and Oceania, enhancing ENT diagnostics with improved visualization and streamlined workflow.
Expansion of Wearable and Remote Cardiac Monitoring Devices
Wearable and remote cardiac monitoring devices are gaining quick adoption in Japan, fueled by the increasing age population and the rising incidence of heart diseases. Smartwatches with built-in ECG, hand-carried Holter monitors, and implantable cardiac event recorders are becoming cornerstones of preventive cardiology. The emergence of 5G connectivity is accelerating real-time data transmission, allowing doctors to monitor patients remotely and catch anomalies before critical events. Japanese device makers are creating small, easy-to-use wearables with longer battery life to drive patient compliance. PMDA support is driving speedy approvals of cutting-edge telemedicine solutions as the nation accelerates healthcare digitalization. Insurers are starting to reimburse for remote monitoring services, further driving market expansion. As clinics and hospitals implement cloud-based cardiac monitoring systems, data-driven information is maximizing treatment plans, lowering hospital readmissions, and enhancing patient outcomes in Japan's changing cardiovascular care environment.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.